董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ilan Hadar | 男 | Chairman and Chief Executive Officer and Director | 56 | 60.79万美元 | 1.66 | 2026-08-10 |
| Avner Lushi | 男 | Director | 59 | 6.00万美元 | 0.27 | 2026-08-10 |
| Dror J. Abramov | 男 | Director | 65 | 6.60万美元 | 0.11 | 2026-08-10 |
| Shlomo Noy | 男 | Director | 73 | 7.50万美元 | 0.27 | 2026-08-10 |
| Ruth Alon | 女 | Director | 74 | 6.60万美元 | 0.11 | 2026-08-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ilan Hadar | 男 | Chairman and Chief Executive Officer and Director | 56 | 60.79万美元 | 1.66 | 2026-08-10 |
| Mitchell Shirvan | 男 | Chief Scientific and Development Officer | 72 | 39.28万美元 | 0.88 | 2026-08-10 |
| Mirit Horenshtein Hadar | 女 | Chief Financial Officer and Secretary | 42 | 38.49万美元 | 1.25 | 2026-08-10 |
董事简历
中英对照 | 中文 | 英文- Ilan Hadar
-
Ilan Hadar被任命为New Silexion的首席执行官，全职任职，自BINCE组合生效，并自2024年5月起担任（previoly，Silexion的）董事会主席。Previoly，他从2022年4月起担任Silexion的董事总经理，直到Biness组合。Hadar先生在制药和高科技公司拥有超过20年的跨国管理和企业经验，如下所述，在此期间，他获得了担任Biomotion Sciences等公司董事会宝贵成员的经验和技能。除了目前在Silexion担任的职务外，Hadar先生自2020年11月起担任PainReform Ltd（纳斯达克：PRFX）的首席执行官，他将在完成Biness组合后辞去该职位。在加入PainReform和Silexion之前，Hadar先生曾于2014年至2020年8月在Foamix Pharmaceuticals Ltd.（目前，纳斯达克：VYNE）担任Israel国家经理和首席财务官，在那里他帮助建立了该组织并在美国推出了新的创新外用药物，还专注于资本市场和并购。在任职于Foamix之前，Hadar先生是Pfizer PFR Pharmaceuticals Israel Ltd.的财务总监，负责监督这家大型制药公司当地实体的所有商业、财务和运营活动。在任职于Pfizer之前，Hadar先生曾在数字印刷领域的世界领先公司HP Indigo Ltd.担任财务经理，在此之前，他曾在世界第三大国防公司BAE Systems担任财务总监，负责BAE Systems Israel的所有财务活动。1998年至2006年，Hadar先生在智能视频解决方案的全球领导者Mango DSP担任首席财务官。Hadar先生曾于2019年至2022年担任Israeli上市生物制药公司Kadimastem的董事会成员。他在Jeralem, Israel的Hebrew大学获得了金融和BINESTRENATRE的MBA学位和学士学位。
Ilan Hadar was appointed as Chief Executive Officer of Silexion, serving on a full time basis, effective upon the Biness Combination, and has served as (previoly, Silexion Israel's) Chairman of the Board since May 2024. Previoly, he served as Managing Director of Silexion Israel from April 2022 until the Biness Combination.Immediately prior to his roles at Silexion Israel and company, Mr. Hadar served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) from November 2020 until the consummation of the Biness Combination in August 2024. Prior to joining Painreform and Silexion Israel, Mr. Hadar served as Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August 2020, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital markets and mergers and acquisitions. Before his role at Foamix, Mr. Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Prior to his tenure at Pfizer, Mr. Hadar served as Finance Manager at HP Indigo Ltd., a world leading company in digital printing, and before that, served as Finance Director at BAE Systems, the third largest defense company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr. Hadar was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions. Mr. Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical company from 2019 to 2022. He received his MBA in Finance and Biness Entrepreneurship and BA from The Hebrew University in Jeralem, Israel. - Ilan Hadar被任命为New Silexion的首席执行官，全职任职，自BINCE组合生效，并自2024年5月起担任（previoly，Silexion的）董事会主席。Previoly，他从2022年4月起担任Silexion的董事总经理，直到Biness组合。Hadar先生在制药和高科技公司拥有超过20年的跨国管理和企业经验，如下所述，在此期间，他获得了担任Biomotion Sciences等公司董事会宝贵成员的经验和技能。除了目前在Silexion担任的职务外，Hadar先生自2020年11月起担任PainReform Ltd（纳斯达克：PRFX）的首席执行官，他将在完成Biness组合后辞去该职位。在加入PainReform和Silexion之前，Hadar先生曾于2014年至2020年8月在Foamix Pharmaceuticals Ltd.（目前，纳斯达克：VYNE）担任Israel国家经理和首席财务官，在那里他帮助建立了该组织并在美国推出了新的创新外用药物，还专注于资本市场和并购。在任职于Foamix之前，Hadar先生是Pfizer PFR Pharmaceuticals Israel Ltd.的财务总监，负责监督这家大型制药公司当地实体的所有商业、财务和运营活动。在任职于Pfizer之前，Hadar先生曾在数字印刷领域的世界领先公司HP Indigo Ltd.担任财务经理，在此之前，他曾在世界第三大国防公司BAE Systems担任财务总监，负责BAE Systems Israel的所有财务活动。1998年至2006年，Hadar先生在智能视频解决方案的全球领导者Mango DSP担任首席财务官。Hadar先生曾于2019年至2022年担任Israeli上市生物制药公司Kadimastem的董事会成员。他在Jeralem, Israel的Hebrew大学获得了金融和BINESTRENATRE的MBA学位和学士学位。
- Ilan Hadar was appointed as Chief Executive Officer of Silexion, serving on a full time basis, effective upon the Biness Combination, and has served as (previoly, Silexion Israel's) Chairman of the Board since May 2024. Previoly, he served as Managing Director of Silexion Israel from April 2022 until the Biness Combination.Immediately prior to his roles at Silexion Israel and company, Mr. Hadar served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) from November 2020 until the consummation of the Biness Combination in August 2024. Prior to joining Painreform and Silexion Israel, Mr. Hadar served as Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August 2020, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital markets and mergers and acquisitions. Before his role at Foamix, Mr. Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Prior to his tenure at Pfizer, Mr. Hadar served as Finance Manager at HP Indigo Ltd., a world leading company in digital printing, and before that, served as Finance Director at BAE Systems, the third largest defense company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr. Hadar was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions. Mr. Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical company from 2019 to 2022. He received his MBA in Finance and Biness Entrepreneurship and BA from The Hebrew University in Jeralem, Israel.
- Avner Lushi
-
Avner Lushi自2020年1月起担任我们的董事，目前是我们审计委员会的成员。他曾共同创立广州中以生物产业投资基金GIBF，专注于将以色列和西方生命科学公司引入中国市场，在那里他也曾担任管理合伙人兼首席执行官。2004年至2015年，Lushi先生担任生命科学风险投资基金Israel梦百合Ventures（IHCV）的合伙人兼董事总经理。从2001年到2005年，他共同创立并担任Life Sciences Transaction Support Ltd.（LTS）（普华永道的子公司，处理生命科学投资银行业务）的首席执行官。Lushi先生曾在七家上市公司担任独立董事，最后活跃的两家是Raval ICS Ltd.和Ram-On Investments and Holdings-1999Ltd.。此外，他担任几家私人公司的董事会成员，作为他在GIBF的角色的一部分。在转向私营部门之前的1997年至2001年，他在以色列总理办公室和以色列最高法院担任越来越高级的职务。Lushi先生拥有耶路撒冷希伯来大学（Hebrew University of Jerusalem）法学硕士学位，海法大学（Haifa University）法学学士学位和经济学学士学位。
Avner Lushi has served as a member of Board of Directors since January 2020 and currently serves as a member of audit committee and Brainsway Ltd.'s nomination committee. Mr. Lushi co founded the Guangzhou Sino Israel Bio industry Investment Fund (GIBF) which focuses on introducing Israeli and western life sciences companies to the Chinese market (and related investments), where he also serves as a Managing Partner & CEO. Between 2004 and 2015 Mr. Lushi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV), a life sciences venture capital fund. From 2001 to 2005, he co founded and served as CEO of Life Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr. Lushi served as an independent board member at ten public companies, of which he remains a board member in Ginegar Plastic Product Ltd. (TASE listed). In addition, as part of his role at GIBF, he serves as a board member of Silexion Therapeutics Corp. (Nasdaq listed) and of several private companies. From 1997 to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister's Chamber and the Israeli Supreme Court. Mr. Lushi holds an LLM in Law from the Hebrew University of Jerusalem, and an LLB in Law and a BA in Economics from the Haifa University. - Avner Lushi自2020年1月起担任我们的董事，目前是我们审计委员会的成员。他曾共同创立广州中以生物产业投资基金GIBF，专注于将以色列和西方生命科学公司引入中国市场，在那里他也曾担任管理合伙人兼首席执行官。2004年至2015年，Lushi先生担任生命科学风险投资基金Israel梦百合Ventures（IHCV）的合伙人兼董事总经理。从2001年到2005年，他共同创立并担任Life Sciences Transaction Support Ltd.（LTS）（普华永道的子公司，处理生命科学投资银行业务）的首席执行官。Lushi先生曾在七家上市公司担任独立董事，最后活跃的两家是Raval ICS Ltd.和Ram-On Investments and Holdings-1999Ltd.。此外，他担任几家私人公司的董事会成员，作为他在GIBF的角色的一部分。在转向私营部门之前的1997年至2001年，他在以色列总理办公室和以色列最高法院担任越来越高级的职务。Lushi先生拥有耶路撒冷希伯来大学（Hebrew University of Jerusalem）法学硕士学位，海法大学（Haifa University）法学学士学位和经济学学士学位。
- Avner Lushi has served as a member of Board of Directors since January 2020 and currently serves as a member of audit committee and Brainsway Ltd.'s nomination committee. Mr. Lushi co founded the Guangzhou Sino Israel Bio industry Investment Fund (GIBF) which focuses on introducing Israeli and western life sciences companies to the Chinese market (and related investments), where he also serves as a Managing Partner & CEO. Between 2004 and 2015 Mr. Lushi served as a Partner and Managing Director of Israel Healthcare Ventures (IHCV), a life sciences venture capital fund. From 2001 to 2005, he co founded and served as CEO of Life Sciences Transaction Support Ltd. (LTS), a PwC subsidiary dealing with life sciences investment banking. Since 2005, Mr. Lushi served as an independent board member at ten public companies, of which he remains a board member in Ginegar Plastic Product Ltd. (TASE listed). In addition, as part of his role at GIBF, he serves as a board member of Silexion Therapeutics Corp. (Nasdaq listed) and of several private companies. From 1997 to 2001, prior to turning to the private sector, he held increasingly senior roles within the Israeli Prime Minister's Chamber and the Israeli Supreme Court. Mr. Lushi holds an LLM in Law from the Hebrew University of Jerusalem, and an LLB in Law and a BA in Economics from the Haifa University.
- Dror J. Abramov
-
Dror J. Abramov，被任命为New Silexion的董事。Abramov先生在动态环境中担任不断变化和成长的公司和市场的多个角色超过15年的经验，特别是他在研发、咨询、税收、销售、业务发展、金融和政府方面的多学科经验，使他成为Biomotion Sciences的适当董事会成员。Abramov先生自2015年起担任惠普企业以色列公司的董事总经理。Abramov先生于2006年至2015年期间曾在惠普企业 Inc. Israel担任其他几个管理职务，包括财务总监、成像和打印部门总经理以及打印和个人系统部门总经理。从2002年到2006年，Abramov先生担任应用材料英国公司和应用材料以色列公司的首席财务官，这两家公司均隶属于应用材料公司（纳斯达克：AMAT），这是一家纳米制造公司，为电子用半导体芯片的制造提供设备、服务和软件。从2000年到2002年，Abramov先生在云通信和工作流协作技术公司Avaya Communication担任业务管理副总裁。从1997年到2000年，阿布拉莫夫先生在Mainsoft Corporation任职，先是担任财务和运营总监，后来担任总经理。从1991年到1997年，Abramov先生在以色列注册会计师事务所Maron，Sobel，Shor & Co.担任顾问和经理。Abramov先生是一名持牌注册会计师，拥有会计学学士、工商管理硕士和物理和计算机科学理学学士学位，这三个学位均来自特拉维夫大学。
Dror J. Abramov was appointed as a director of Silexion effective upon the consummation of the Biness Combination. Mr. Abramov's experience of over 15 years in multiple roles in changing and growing companies and markets within dynamic environments, and in particular his multi disciplinary experience in R&D, consulting, taxes, sales, biness development, finance and government, lend to his being an appropriate board member of company. Mr. Abramov has served as Managing Director of Hewlett Packard Inc. Israel since 2015. Mr. Abramov held several other management positions in Hewlett Packard Inc. Israel from 2006 to 2015, including finance director, general manager of imaging and printing divisions and general manager of printing and personal systems division. From 2002 through 2006, Mr. Abramov served as Chief Financial Officer of Applied Materials UK and Applied Materials Israel, both part of Applied Materials, Inc. (Nasdaq: AMAT), a nanomanufacturing company that supplies equipment, services and software for the manufacture of semiconductor chips for electronics. From 2000 through 2002, Mr. Abramov served as Vice President of biness management at Avaya Communication, a cloud communications and workstream collaboration technology company. From 1997 until 2000, Mr. Abramov held positions in Mainsoft Corporation, first as director of finance and operations and later as general manager. From 1991 through 1997, Mr. Abramov served as consultant and manager at Maron, Sobel, Shor & Co., an Israeli CPA firm. Mr. Abramov is a licensed CPA and holds a Bachelor of Accounting, Master of Biness Administration and Bachelor of Science in physics and computer sciences, all three degrees from Tel Aviv University. - Dror J. Abramov，被任命为New Silexion的董事。Abramov先生在动态环境中担任不断变化和成长的公司和市场的多个角色超过15年的经验，特别是他在研发、咨询、税收、销售、业务发展、金融和政府方面的多学科经验，使他成为Biomotion Sciences的适当董事会成员。Abramov先生自2015年起担任惠普企业以色列公司的董事总经理。Abramov先生于2006年至2015年期间曾在惠普企业 Inc. Israel担任其他几个管理职务，包括财务总监、成像和打印部门总经理以及打印和个人系统部门总经理。从2002年到2006年，Abramov先生担任应用材料英国公司和应用材料以色列公司的首席财务官，这两家公司均隶属于应用材料公司（纳斯达克：AMAT），这是一家纳米制造公司，为电子用半导体芯片的制造提供设备、服务和软件。从2000年到2002年，Abramov先生在云通信和工作流协作技术公司Avaya Communication担任业务管理副总裁。从1997年到2000年，阿布拉莫夫先生在Mainsoft Corporation任职，先是担任财务和运营总监，后来担任总经理。从1991年到1997年，Abramov先生在以色列注册会计师事务所Maron，Sobel，Shor & Co.担任顾问和经理。Abramov先生是一名持牌注册会计师，拥有会计学学士、工商管理硕士和物理和计算机科学理学学士学位，这三个学位均来自特拉维夫大学。
- Dror J. Abramov was appointed as a director of Silexion effective upon the consummation of the Biness Combination. Mr. Abramov's experience of over 15 years in multiple roles in changing and growing companies and markets within dynamic environments, and in particular his multi disciplinary experience in R&D, consulting, taxes, sales, biness development, finance and government, lend to his being an appropriate board member of company. Mr. Abramov has served as Managing Director of Hewlett Packard Inc. Israel since 2015. Mr. Abramov held several other management positions in Hewlett Packard Inc. Israel from 2006 to 2015, including finance director, general manager of imaging and printing divisions and general manager of printing and personal systems division. From 2002 through 2006, Mr. Abramov served as Chief Financial Officer of Applied Materials UK and Applied Materials Israel, both part of Applied Materials, Inc. (Nasdaq: AMAT), a nanomanufacturing company that supplies equipment, services and software for the manufacture of semiconductor chips for electronics. From 2000 through 2002, Mr. Abramov served as Vice President of biness management at Avaya Communication, a cloud communications and workstream collaboration technology company. From 1997 until 2000, Mr. Abramov held positions in Mainsoft Corporation, first as director of finance and operations and later as general manager. From 1991 through 1997, Mr. Abramov served as consultant and manager at Maron, Sobel, Shor & Co., an Israeli CPA firm. Mr. Abramov is a licensed CPA and holds a Bachelor of Accounting, Master of Biness Administration and Bachelor of Science in physics and computer sciences, all three degrees from Tel Aviv University.
- Shlomo Noy
-
Shlomo Noy，被任命为New Silexion的董事。Noy教授在医疗保健管理、技术转让、建立生态系统以及将医院重点放在研究和临床试验方面的国际水平的专业知识将为Biomotion Sciences董事会在以色列研究和临床试验活动领域提供重要知识。诺伊教授自2017年1月起担任GIBF首席医疗官。诺伊教授曾于1993年至2017年担任Sheba医疗中心康复医院院长，并于2000年至2017年担任Sheba医疗中心研发和学术事务副总裁。诺伊教授于1993年至2016年担任特拉维夫大学萨克勒医学院教授。诺伊教授担任多家私营公司的董事会成员，这是他在GIBF工作的一部分。诺伊教授拥有25年的医疗保健管理经验，积极推动以色列国家一级以及国际一级的研究和教育。Noy教授在以色列耶路撒冷哈大沙医学院希伯来大学获得医学博士学位，并在法国枫丹白露欧洲工商管理学院（INSEAD）完成MBA学位，拥有特拉维夫大学医学与管理学院博士学位。
Shlomo Noy was appointed as a director of Silexion effective upon the consummation of the Biness Combination. Professor Noy's international level expertise in healthcare management, tech transfer, building ecosystems and focing hospitals on research and clinical trials provides important knowledge to board of directors in the realm of Israeli research and clinical trial activities. Professor Noy has served as Chief Medical Officer of GIBF since January 2017. Professor Noy served as the Director of the Rehabilitation Hospital at Sheba Medical Center from 1993 to 2017 and Vice President of Research and Development and Academic Affairs at Sheba Medical Center from 2000 to 2017. Prof. Noy was a Professor at Sackler School of Medicine at Tel Aviv University from 1993 to 2016. Prof. Noy serves as a board member of several private companies as part of his role at GIBF. Prof. Noy possesses 25 years' experience in health care management and is active in promoting research and education at an Israeli national level as ll as at an international level. Prof. Noy received his MD from the Hebrew University, Hadassah Medical School, Jeralem, Israel, and completed his MBA at the European School of Biness Administration (INSEAD) Fontainebleau, France, and holds a PhD degree from Tel Aviv University, Faculty of Medicine and Management. - Shlomo Noy，被任命为New Silexion的董事。Noy教授在医疗保健管理、技术转让、建立生态系统以及将医院重点放在研究和临床试验方面的国际水平的专业知识将为Biomotion Sciences董事会在以色列研究和临床试验活动领域提供重要知识。诺伊教授自2017年1月起担任GIBF首席医疗官。诺伊教授曾于1993年至2017年担任Sheba医疗中心康复医院院长，并于2000年至2017年担任Sheba医疗中心研发和学术事务副总裁。诺伊教授于1993年至2016年担任特拉维夫大学萨克勒医学院教授。诺伊教授担任多家私营公司的董事会成员，这是他在GIBF工作的一部分。诺伊教授拥有25年的医疗保健管理经验，积极推动以色列国家一级以及国际一级的研究和教育。Noy教授在以色列耶路撒冷哈大沙医学院希伯来大学获得医学博士学位，并在法国枫丹白露欧洲工商管理学院（INSEAD）完成MBA学位，拥有特拉维夫大学医学与管理学院博士学位。
- Shlomo Noy was appointed as a director of Silexion effective upon the consummation of the Biness Combination. Professor Noy's international level expertise in healthcare management, tech transfer, building ecosystems and focing hospitals on research and clinical trials provides important knowledge to board of directors in the realm of Israeli research and clinical trial activities. Professor Noy has served as Chief Medical Officer of GIBF since January 2017. Professor Noy served as the Director of the Rehabilitation Hospital at Sheba Medical Center from 1993 to 2017 and Vice President of Research and Development and Academic Affairs at Sheba Medical Center from 2000 to 2017. Prof. Noy was a Professor at Sackler School of Medicine at Tel Aviv University from 1993 to 2016. Prof. Noy serves as a board member of several private companies as part of his role at GIBF. Prof. Noy possesses 25 years' experience in health care management and is active in promoting research and education at an Israeli national level as ll as at an international level. Prof. Noy received his MD from the Hebrew University, Hadassah Medical School, Jeralem, Israel, and completed his MBA at the European School of Biness Administration (INSEAD) Fontainebleau, France, and holds a PhD degree from Tel Aviv University, Faculty of Medicine and Management.
- Ruth Alon
-
Ruth Alon成为New Silexion的董事。Alon女士在高科技医疗行业和以色列生命科学公司拥有超过30年的国际经验，特别是使她成为Biomotion sciences董事会的潜在有价值成员。她是Medstrada的创始人兼首席执行官，该公司成立于2016年。从1997年到2016年，她担任Pitango Venture Capital的普通合伙人，在那里她领导生命科学活动，并帮助促进收购公司的几个投资组合公司。目前，她还担任多家私人和上市公司的董事会成员或主席，包括Vascular Biogenics Ltd.（纳斯达克股票代码：VBLT）、Brainsgate和KadimaStem。她曾在华尔街工作，担任Montgomery Securities（1981年至1987年）和Kidder Peabody & Co.（1987年至1993年）的高级医疗设备分析师。1995年至1996年，她还在旧金山管理自己的独立咨询业务，为医疗设备行业的早期公司和风险资本家提供广泛的服务。2005年，她还在Israel Life Science Industry （ILSI）（一个非营利性组织，截至2005年，代表了大约700家以色列生命科学公司的共同目标）的建立中发挥了重要作用。她是IATI的联合创始人，IATI是一个伞形组织，成立于2012年，代表以色列的高科技和生命科学行业。她持有the Hebrew Jerusalem大学的经济学学士学位、Boston大学的工商管理硕士学位和Columbia大学School of Physicians and Surgeons的硕士学位。
Ruth Alon became a director of Silexion effective upon the consummation of the Biness Combination. Ms. Alon's international experience of over 30 years in the high tech medical industry and with Israeli life sciences companies, in particular, make her a valuable member of board of directors. Ms. Alon is the Founder and Chief Executive Officer of Medstrada, which was started in 2016. From 1997 until 2016, Ms. Alon served as a General Partner in Pitango Venture Capital, where she headed the life sciences activities and helped to facilitate the acquisition of several of the company'sportfolio companies. Currently, Ms. Alon also serves on the board of directors of a number of private and public companies as a member or chairperson, Alpha Tau medical (Nasdaq: DRTS), Brainsgate, Treos Bio, Angiolutions and CorNeat Vision. Ms. Alon previoly worked on Wall Street where she held senior positions as a senior medical device analyst with Montgomery Securities (from 1981 to 1987) and Kidder Peabody & Co. (from 1987 to 1993). She also managed her own independent consulting biness in San Francisco from 1995 to 1996, providing broad based services to early stage companies and venture capitalists in the medical devices industry. Ms. Alon was also instrumental in the establishment, in 2005, of Israel Life Science industry (ILSI), a not for profit organization which represented, as of 2005, the mutual goals of approximately 700 Israeli life science companies. She is the Co Founder of IATI, an umbrella organization established in 2012, representing Israel's High Tech and Life Sciences indtries. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jeralem, an M.B.A. from Boston University, and an M.Sc. from the Columbia University School of Physicians and Surgeons. - Ruth Alon成为New Silexion的董事。Alon女士在高科技医疗行业和以色列生命科学公司拥有超过30年的国际经验，特别是使她成为Biomotion sciences董事会的潜在有价值成员。她是Medstrada的创始人兼首席执行官，该公司成立于2016年。从1997年到2016年，她担任Pitango Venture Capital的普通合伙人，在那里她领导生命科学活动，并帮助促进收购公司的几个投资组合公司。目前，她还担任多家私人和上市公司的董事会成员或主席，包括Vascular Biogenics Ltd.（纳斯达克股票代码：VBLT）、Brainsgate和KadimaStem。她曾在华尔街工作，担任Montgomery Securities（1981年至1987年）和Kidder Peabody & Co.（1987年至1993年）的高级医疗设备分析师。1995年至1996年，她还在旧金山管理自己的独立咨询业务，为医疗设备行业的早期公司和风险资本家提供广泛的服务。2005年，她还在Israel Life Science Industry （ILSI）（一个非营利性组织，截至2005年，代表了大约700家以色列生命科学公司的共同目标）的建立中发挥了重要作用。她是IATI的联合创始人，IATI是一个伞形组织，成立于2012年，代表以色列的高科技和生命科学行业。她持有the Hebrew Jerusalem大学的经济学学士学位、Boston大学的工商管理硕士学位和Columbia大学School of Physicians and Surgeons的硕士学位。
- Ruth Alon became a director of Silexion effective upon the consummation of the Biness Combination. Ms. Alon's international experience of over 30 years in the high tech medical industry and with Israeli life sciences companies, in particular, make her a valuable member of board of directors. Ms. Alon is the Founder and Chief Executive Officer of Medstrada, which was started in 2016. From 1997 until 2016, Ms. Alon served as a General Partner in Pitango Venture Capital, where she headed the life sciences activities and helped to facilitate the acquisition of several of the company'sportfolio companies. Currently, Ms. Alon also serves on the board of directors of a number of private and public companies as a member or chairperson, Alpha Tau medical (Nasdaq: DRTS), Brainsgate, Treos Bio, Angiolutions and CorNeat Vision. Ms. Alon previoly worked on Wall Street where she held senior positions as a senior medical device analyst with Montgomery Securities (from 1981 to 1987) and Kidder Peabody & Co. (from 1987 to 1993). She also managed her own independent consulting biness in San Francisco from 1995 to 1996, providing broad based services to early stage companies and venture capitalists in the medical devices industry. Ms. Alon was also instrumental in the establishment, in 2005, of Israel Life Science industry (ILSI), a not for profit organization which represented, as of 2005, the mutual goals of approximately 700 Israeli life science companies. She is the Co Founder of IATI, an umbrella organization established in 2012, representing Israel's High Tech and Life Sciences indtries. Ms. Alon holds a B.A. in Economics from the Hebrew University of Jeralem, an M.B.A. from Boston University, and an M.Sc. from the Columbia University School of Physicians and Surgeons.
高管简历
中英对照 | 中文 | 英文- Ilan Hadar
Ilan Hadar被任命为New Silexion的首席执行官，全职任职，自BINCE组合生效，并自2024年5月起担任（previoly，Silexion的）董事会主席。Previoly，他从2022年4月起担任Silexion的董事总经理，直到Biness组合。Hadar先生在制药和高科技公司拥有超过20年的跨国管理和企业经验，如下所述，在此期间，他获得了担任Biomotion Sciences等公司董事会宝贵成员的经验和技能。除了目前在Silexion担任的职务外，Hadar先生自2020年11月起担任PainReform Ltd（纳斯达克：PRFX）的首席执行官，他将在完成Biness组合后辞去该职位。在加入PainReform和Silexion之前，Hadar先生曾于2014年至2020年8月在Foamix Pharmaceuticals Ltd.（目前，纳斯达克：VYNE）担任Israel国家经理和首席财务官，在那里他帮助建立了该组织并在美国推出了新的创新外用药物，还专注于资本市场和并购。在任职于Foamix之前，Hadar先生是Pfizer PFR Pharmaceuticals Israel Ltd.的财务总监，负责监督这家大型制药公司当地实体的所有商业、财务和运营活动。在任职于Pfizer之前，Hadar先生曾在数字印刷领域的世界领先公司HP Indigo Ltd.担任财务经理，在此之前，他曾在世界第三大国防公司BAE Systems担任财务总监，负责BAE Systems Israel的所有财务活动。1998年至2006年，Hadar先生在智能视频解决方案的全球领导者Mango DSP担任首席财务官。Hadar先生曾于2019年至2022年担任Israeli上市生物制药公司Kadimastem的董事会成员。他在Jeralem, Israel的Hebrew大学获得了金融和BINESTRENATRE的MBA学位和学士学位。
Ilan Hadar was appointed as Chief Executive Officer of Silexion, serving on a full time basis, effective upon the Biness Combination, and has served as (previoly, Silexion Israel's) Chairman of the Board since May 2024. Previoly, he served as Managing Director of Silexion Israel from April 2022 until the Biness Combination.Immediately prior to his roles at Silexion Israel and company, Mr. Hadar served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) from November 2020 until the consummation of the Biness Combination in August 2024. Prior to joining Painreform and Silexion Israel, Mr. Hadar served as Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August 2020, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital markets and mergers and acquisitions. Before his role at Foamix, Mr. Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Prior to his tenure at Pfizer, Mr. Hadar served as Finance Manager at HP Indigo Ltd., a world leading company in digital printing, and before that, served as Finance Director at BAE Systems, the third largest defense company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr. Hadar was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions. Mr. Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical company from 2019 to 2022. He received his MBA in Finance and Biness Entrepreneurship and BA from The Hebrew University in Jeralem, Israel.- Ilan Hadar被任命为New Silexion的首席执行官，全职任职，自BINCE组合生效，并自2024年5月起担任（previoly，Silexion的）董事会主席。Previoly，他从2022年4月起担任Silexion的董事总经理，直到Biness组合。Hadar先生在制药和高科技公司拥有超过20年的跨国管理和企业经验，如下所述，在此期间，他获得了担任Biomotion Sciences等公司董事会宝贵成员的经验和技能。除了目前在Silexion担任的职务外，Hadar先生自2020年11月起担任PainReform Ltd（纳斯达克：PRFX）的首席执行官，他将在完成Biness组合后辞去该职位。在加入PainReform和Silexion之前，Hadar先生曾于2014年至2020年8月在Foamix Pharmaceuticals Ltd.（目前，纳斯达克：VYNE）担任Israel国家经理和首席财务官，在那里他帮助建立了该组织并在美国推出了新的创新外用药物，还专注于资本市场和并购。在任职于Foamix之前，Hadar先生是Pfizer PFR Pharmaceuticals Israel Ltd.的财务总监，负责监督这家大型制药公司当地实体的所有商业、财务和运营活动。在任职于Pfizer之前，Hadar先生曾在数字印刷领域的世界领先公司HP Indigo Ltd.担任财务经理，在此之前，他曾在世界第三大国防公司BAE Systems担任财务总监，负责BAE Systems Israel的所有财务活动。1998年至2006年，Hadar先生在智能视频解决方案的全球领导者Mango DSP担任首席财务官。Hadar先生曾于2019年至2022年担任Israeli上市生物制药公司Kadimastem的董事会成员。他在Jeralem, Israel的Hebrew大学获得了金融和BINESTRENATRE的MBA学位和学士学位。
- Ilan Hadar was appointed as Chief Executive Officer of Silexion, serving on a full time basis, effective upon the Biness Combination, and has served as (previoly, Silexion Israel's) Chairman of the Board since May 2024. Previoly, he served as Managing Director of Silexion Israel from April 2022 until the Biness Combination.Immediately prior to his roles at Silexion Israel and company, Mr. Hadar served as the Chief Executive Officer of Painreform Ltd (Nasdaq: PRFX) from November 2020 until the consummation of the Biness Combination in August 2024. Prior to joining Painreform and Silexion Israel, Mr. Hadar served as Country Manager Israel and Chief Financial Officer at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from 2014 until August 2020, where he was instrumental in building the organization and launching new innovative topical drugs in the U.S., and also focused on capital markets and mergers and acquisitions. Before his role at Foamix, Mr. Hadar was Finance Director at Pfizer PFR Pharmaceuticals Israel Ltd., where he oversaw all commercial, financial and operational activities of the local entity of the large pharmaceutical company. Prior to his tenure at Pfizer, Mr. Hadar served as Finance Manager at HP Indigo Ltd., a world leading company in digital printing, and before that, served as Finance Director at BAE Systems, the third largest defense company in the world, where he was responsible for all financial activities of BAE Systems Israel. From 1998 to 2006, Mr. Hadar was Chief Financial Officer at Mango DSP, a global leader of Intelligent Video Solutions. Mr. Hadar served on the board of directors of Kadimastem, a public Israeli biopharmaceutical company from 2019 to 2022. He received his MBA in Finance and Biness Entrepreneurship and BA from The Hebrew University in Jeralem, Israel.
- Mitchell Shirvan
Mitchell Shirvan，自业务合并以来一直担任New Silexion的首席科学与发展官，在业务合并之前，自2022年4月起担任Silexion的首席科学与发展官。在加入Silexion之前，Shirvan博士曾于2014年至2019年在Foamix制药有限公司担任研发和VP创新与发现高级副总裁。Shirvan博士拥有超过25年的行业经验，此前曾于2008年至2012年在Macrocure有限公司担任首席执行官。从1992年到2008年，Shirvan博士在梯瓦制药担任过越来越重要的多个职位，包括战略业务规划高级总监和研发高级经理。在Teva任职之前，他是美国国立卫生研究院的研究员。Shirvan博士拥有耶路撒冷希伯来大学微生物学博士学位和布拉德福德大学MBA学位。
Mitchell Shirvan has served as the Chief Scientific and Development Officer of Silexion since the Biness Combination, and, before the Biness Combination, of Silexion Israel, since April 2022. Prior to joining Silexion Israel, Dr. Shirvan served as the Senior Vice President of R&D and V.P. Innovation and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr. Shirvan has over 25 years of industry experience, previoly holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr. Shirvan held vario positions of increasing responsibility at Teva Pharmaceutical Indtries, including Senior Director, Strategic Biness Planning and Senior Manager, Research & Development. Prior to his tenure at Teva, he was a research fellow at the U.S. National Institutes of Health. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jeralem and an MBA from the University of Bradford.- Mitchell Shirvan，自业务合并以来一直担任New Silexion的首席科学与发展官，在业务合并之前，自2022年4月起担任Silexion的首席科学与发展官。在加入Silexion之前，Shirvan博士曾于2014年至2019年在Foamix制药有限公司担任研发和VP创新与发现高级副总裁。Shirvan博士拥有超过25年的行业经验，此前曾于2008年至2012年在Macrocure有限公司担任首席执行官。从1992年到2008年，Shirvan博士在梯瓦制药担任过越来越重要的多个职位，包括战略业务规划高级总监和研发高级经理。在Teva任职之前，他是美国国立卫生研究院的研究员。Shirvan博士拥有耶路撒冷希伯来大学微生物学博士学位和布拉德福德大学MBA学位。
- Mitchell Shirvan has served as the Chief Scientific and Development Officer of Silexion since the Biness Combination, and, before the Biness Combination, of Silexion Israel, since April 2022. Prior to joining Silexion Israel, Dr. Shirvan served as the Senior Vice President of R&D and V.P. Innovation and Discovery at Foamix Pharmaceuticals Ltd. from 2014 to 2019. Dr. Shirvan has over 25 years of industry experience, previoly holding positions as Chief Executive Officer at Macrocure Ltd. from 2008 to 2012. From 1992 until 2008, Dr. Shirvan held vario positions of increasing responsibility at Teva Pharmaceutical Indtries, including Senior Director, Strategic Biness Planning and Senior Manager, Research & Development. Prior to his tenure at Teva, he was a research fellow at the U.S. National Institutes of Health. Dr. Shirvan holds a Ph.D. in microbiology from The Hebrew University of Jeralem and an MBA from the University of Bradford.
- Mirit Horenshtein Hadar
Mirit Horenshtein Hadar，注册会计师，自Biness合并以来一直担任Silexion的首席财务官和秘书，并在Biness合并之前担任Silexion Israel的财务事务执行副总裁，自2024年1月开始。从2023年8月至2024年1月，Horenshtein Hadar女士担任战略与企业融资咨询职位的兼职顾问。Horenshtein Hadar女士在上市公司和私营公司的高级财务职位、制药和高科技行业拥有超过17年的公司财务经验，她在建立促进增长的金融基础设施、美国公认会计原则财务报告和FP & A职能方面发挥了重要作用，并领导了复杂并购交易、整合流程和公开发行的会计和报告工作。在加入Silexion Israel之前，2021年1月至2022年12月，Horenshtein Hadar女士曾担任Gauzy Ltd.（现为纳斯达克：GAUZ）的财务副总裁兼CFO Israel，该公司是一家纳米技术公司，开发和营销智能玻璃和视觉控制技术。从2022年12月到2025年7月，Horenshtein Hadar女士担任Gauzy财务部门的外部顾问。在加入Gauzy之前，Horenshtein Hadar女士于2016年7月至2020年12月期间在Foamix Pharmaceuticals Ltd.（目前，纳斯达克：VYNE）担任财务高级总监兼FP & A、会计和财务报告主管。在加入Foamix之前，Horenshtein Hadar女士于2008年至2016年担任普华永道以色列公司的高级经理，担任外部审计师。Horenshtein Hadar女士于2011年成为合格的注册会计师，并获得特拉维夫大学会计、经济学和BINCE管理学士学位。
Mirit Horenshtein Hadar has served as the Chief Financial Officer and Secretary of Silexion since the Biness Combination, and served as the Executive Vice President of Finance Affairs at Silexion Israel before the Biness Combination, beginning in January 2024. From August 2023 to January 2024, Ms. Horenshtein Hadar served as a part time consultant in a Strategy & Corporate Finance Advisory capacity. Ms. Horenshtein Hadar has over 17 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high tech indtries, where she has been instrumental in building financial infrastructures for growth, U.S. GAAP financial reporting and FP&A functions, and has led the accounting and reporting of complex M&A transactions, integration processes and public offerings. Prior to joining Silexion Israel, from January 2021 to December 2022, Ms. Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd. (currently, Nasdaq: GAUZ), a nanotechnology company that develops and markets smart glass and vision control technologies. From December 2022 through July 2025, Ms. Horenshtein Hadar served as an external advisor to the finance department at Gauzy. Prior to Gauzy, Ms. Horenshtein Hadar served as Senior Director of Finance and Head of FP&A, Accounting and Financial Reporting at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from July 2016 until December 2020. Prior to Foamix, Ms. Horenshtein Hadar was a Senior Manager at PwC Israel, as an external auditor, from 2008 to 2016. Ms. Horenshtein Hadar became a Qualified CPA in 2011 and received a BA in Accounting, Economics and Biness Management from Tel Aviv University.- Mirit Horenshtein Hadar，注册会计师，自Biness合并以来一直担任Silexion的首席财务官和秘书，并在Biness合并之前担任Silexion Israel的财务事务执行副总裁，自2024年1月开始。从2023年8月至2024年1月，Horenshtein Hadar女士担任战略与企业融资咨询职位的兼职顾问。Horenshtein Hadar女士在上市公司和私营公司的高级财务职位、制药和高科技行业拥有超过17年的公司财务经验，她在建立促进增长的金融基础设施、美国公认会计原则财务报告和FP & A职能方面发挥了重要作用，并领导了复杂并购交易、整合流程和公开发行的会计和报告工作。在加入Silexion Israel之前，2021年1月至2022年12月，Horenshtein Hadar女士曾担任Gauzy Ltd.（现为纳斯达克：GAUZ）的财务副总裁兼CFO Israel，该公司是一家纳米技术公司，开发和营销智能玻璃和视觉控制技术。从2022年12月到2025年7月，Horenshtein Hadar女士担任Gauzy财务部门的外部顾问。在加入Gauzy之前，Horenshtein Hadar女士于2016年7月至2020年12月期间在Foamix Pharmaceuticals Ltd.（目前，纳斯达克：VYNE）担任财务高级总监兼FP & A、会计和财务报告主管。在加入Foamix之前，Horenshtein Hadar女士于2008年至2016年担任普华永道以色列公司的高级经理，担任外部审计师。Horenshtein Hadar女士于2011年成为合格的注册会计师，并获得特拉维夫大学会计、经济学和BINCE管理学士学位。
- Mirit Horenshtein Hadar has served as the Chief Financial Officer and Secretary of Silexion since the Biness Combination, and served as the Executive Vice President of Finance Affairs at Silexion Israel before the Biness Combination, beginning in January 2024. From August 2023 to January 2024, Ms. Horenshtein Hadar served as a part time consultant in a Strategy & Corporate Finance Advisory capacity. Ms. Horenshtein Hadar has over 17 years of corporate finance experience in senior financial positions of public companies and privately held companies, in the pharmaceutical and high tech indtries, where she has been instrumental in building financial infrastructures for growth, U.S. GAAP financial reporting and FP&A functions, and has led the accounting and reporting of complex M&A transactions, integration processes and public offerings. Prior to joining Silexion Israel, from January 2021 to December 2022, Ms. Horenshtein Hadar served as VP of Finance and then CFO Israel of Gauzy Ltd. (currently, Nasdaq: GAUZ), a nanotechnology company that develops and markets smart glass and vision control technologies. From December 2022 through July 2025, Ms. Horenshtein Hadar served as an external advisor to the finance department at Gauzy. Prior to Gauzy, Ms. Horenshtein Hadar served as Senior Director of Finance and Head of FP&A, Accounting and Financial Reporting at Foamix Pharmaceuticals Ltd. (currently, Nasdaq: VYNE) from July 2016 until December 2020. Prior to Foamix, Ms. Horenshtein Hadar was a Senior Manager at PwC Israel, as an external auditor, from 2008 to 2016. Ms. Horenshtein Hadar became a Qualified CPA in 2011 and received a BA in Accounting, Economics and Biness Management from Tel Aviv University.